TENCENT
00700
TME-SW
01698
XIAOMI-W
01810
ALI HEALTH
00241
KUAISHOU-W
01024
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 15.33%16.26B | 19.99%10.28B | 27.20%3.92B | 20.88%21.8B | 29.60%14.1B | 31.31%8.57B | 21.25%3.09B | 19.26%18.03B | 27.56%10.88B | 23.19%6.53B |
Operating income | 15.33%16.26B | 19.99%10.28B | 27.20%3.92B | 20.88%21.8B | 29.60%14.1B | 31.31%8.57B | 21.25%3.09B | 19.26%18.03B | 27.56%10.88B | 23.19%6.53B |
Operating expenses | -13.49%-11.45B | -19.20%-7.42B | -24.10%-2.59B | -18.77%-14.42B | -38.98%-10.09B | -44.97%-6.23B | -27.56%-2.09B | -21.16%-12.14B | -37.01%-7.26B | -30.12%-4.29B |
Gross profit | 19.96%4.81B | 22.11%2.86B | 33.65%1.34B | 25.22%7.38B | 10.80%4.01B | 5.02%2.34B | 9.93%1B | 15.54%5.89B | 12.04%3.62B | 11.74%2.23B |
Selling expenses | -5.47%-324.85M | -0.56%-203.55M | -41.86%-251.41M | -35.40%-1.49B | 53.24%-307.99M | 49.86%-202.41M | -5.54%-177.22M | -4.55%-1.1B | -3.89%-658.65M | 0.48%-403.72M |
Administrative expenses | -7.82%-672.7M | -12.16%-432.9M | -14.60%-175.05M | -16.99%-1.04B | -21.28%-623.92M | -12.85%-385.95M | -5.92%-152.75M | -9.47%-889.98M | -8.98%-514.43M | -18.39%-342M |
Research and development expenses | -20.98%-1.53B | -16.69%-944.89M | -23.16%-457.34M | -14.70%-2.02B | -18.57%-1.27B | -16.33%-809.73M | -23.41%-371.34M | -4.25%-1.76B | -2.35%-1.07B | -8.60%-696.06M |
Profit from asset sales | 14.85%3.06M | 1,479.35%2.96M | 111.83%39.12K | -31.86%2.78M | 4,724.46%2.67M | -40.38%187.33K | -357.34%-330.56K | 296.74%4.08M | 116.70%55.24K | 256.96%314.2K |
Revaluation surplus | -44.77%31.91M | -33.03%27.78M | -16.19%15.31M | -55.07%74.6M | -58.73%57.77M | -60.98%41.47M | -67.87%18.27M | 133.42%166.03M | 1,340.74%139.99M | 1,096.46%106.3M |
-Changes in the fair value of other assets | -44.77%31.91M | -33.03%27.78M | -16.19%15.31M | -55.07%74.6M | -58.73%57.77M | -60.98%41.47M | -67.87%18.27M | 133.42%166.03M | 1,340.74%139.99M | 1,096.46%106.3M |
Impairment and provision | -35.77%-221.73M | -23.11%-137.75M | -179.43%-46.21M | -3,013.43%-341.09M | -83.20%-163.32M | 28.36%-111.9M | 80.91%-16.54M | 129.24%11.71M | 40.93%-89.15M | -37.29%-156.19M |
-Other impairment is provision | -35.77%-221.73M | -23.11%-137.75M | -179.43%-46.21M | -3,013.43%-341.09M | -83.20%-163.32M | 28.36%-111.9M | 80.91%-16.54M | 129.24%11.71M | 40.93%-89.15M | -37.29%-156.19M |
Special items of operating profit | 62.26%721.56M | 105.82%514.23M | 23.14%165.13M | 15.74%613.68M | 26.25%444.68M | 18.32%249.85M | 29.19%134.1M | -6.44%530.21M | -9.91%352.22M | -15.89%211.16M |
Operating profit | 30.46%2.71B | 49.79%1.62B | 35.25%566.86M | 11.65%3.06B | 21.86%2.07B | 20.20%1.08B | 22.45%419.13M | 35.15%2.74B | 33.25%1.7B | 16.34%902.36M |
Financing cost | -6.82%150.53M | -38.39%78.05M | 1.07%49.17M | 35.05%257.82M | 27.34%161.54M | 36.13%126.68M | 26.46%48.65M | 158.65%190.9M | 311.79%126.85M | 432.27%93.06M |
Special items of earning before tax | 14.21%23.38M | -57.64%6.08M | 120.13%6.53M | 311.22%42.16M | 148.94%20.47M | 369.98%14.36M | 16.84%2.97M | -52.57%10.25M | -46.79%8.22M | -62.79%3.06M |
Earning before tax | 27.65%2.88B | 39.42%1.71B | 32.25%622.56M | 14.21%3.36B | 22.81%2.26B | 22.75%1.23B | 22.82%470.75M | 38.55%2.94B | 38.80%1.84B | 24.61%998.48M |
Tax | -36.45%-212.97M | -188.59%-107.71M | -93.39%-45.07M | 40.07%-209.5M | 40.92%-156.08M | 68.74%-37.32M | 42.21%-23.3M | -295.11%-349.58M | -135.50%-264.19M | -21.41%-119.4M |
After-tax profit from continuing operations | 26.99%2.67B | 34.73%1.6B | 29.07%577.5M | 21.53%3.15B | 33.51%2.1B | 35.18%1.19B | 30.46%447.45M | 27.39%2.59B | 29.85%1.57B | 25.05%879.09M |
Earning after tax | 26.99%2.67B | 34.73%1.6B | 29.07%577.5M | 21.53%3.15B | 33.51%2.1B | 35.18%1.19B | 30.46%447.45M | 27.39%2.59B | 29.85%1.57B | 25.05%879.09M |
Minority profit | 251.25%166.13M | 175.83%94.19M | -19.38%9.95M | 22.80%44.39M | 345.57%47.3M | 320.25%34.15M | 518.87%12.34M | 113.75%36.15M | 14.53%10.62M | 5.01%8.13M |
Profit attributable to shareholders | 21.82%2.5B | 30.56%1.51B | 30.44%567.55M | 21.51%3.11B | 31.39%2.05B | 32.52%1.15B | 27.61%435.1M | 26.67%2.56B | 29.97%1.56B | 25.28%870.96M |
Basic earnings per share | 22.07%1.77 | 32.10%1.07 | 29.03%0.4 | 21.67%2.19 | 31.82%1.45 | 32.79%0.81 | 29.17%0.31 | 10.43%1.8 | 7.84%1.1 | 3.39%0.61 |
Diluted earnings per share | 22.07%1.77 | 32.10%1.07 | 29.03%0.4 | 21.67%2.19 | 31.82%1.45 | 32.79%0.81 | 29.17%0.31 | 1.8 | 7.84%1.1 | 3.39%0.61 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- | -- | KPMG Huazhen Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.